Skip to content

Effect of Ascites Replacement Strategy on Time to 1st Flatus After LDLT

Effect of Albumin Administration Strategy for Ascites Replacement on Time to 1st Flatus After Liver Transplantation

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04184401
Enrollment
72
Registered
2019-12-03
Start date
2020-01-01
Completion date
2021-11-30
Last updated
2023-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Living Donor Liver Transplantation

Keywords

Ascites, Albumin, Hartmann's solution, Postoperative ileus

Brief summary

The aim of this study is to evaluate difference in the rate of recovery of intestinal motility according to different ascites replacement strategy after living donor liver transplantation.

Interventions

DRUGAscites replacement with albumin and hartmann's solution

Combined strategy for ascites replacement * 30% of ascites: replacement with 5% albumin * 40% of ascites: replacement with Hartmann's solution

DRUGAscites replacement with hartmann's solution

Hartmann's solution only strategy for ascites replacement \- 70% of ascites: replacement with Hartmann's solution

Sponsors

Seoul National University Hospital
Lead SponsorOTHER
GC Pharma
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (19 years or older) * Elective living donor liver transplantation

Exclusion criteria

* Previous abdominal surgery * Renal failure requiring renal replacement therapy * Contraindications for 5% albumin use 1. Condition with potential risk caused by increased circulating plasma (heart failure, renal failure combined with oliguria, pulmonary edema) 2. Hemolytic anemia * Contraindications for Hartmann solution 1. Progressive lactic acidosis 2. Hypervolemia 3. Hypernatremia

Design outcomes

Primary

MeasureTime frameDescription
Time to 1st flatuswithin 4 weeksInterval between SICU admission and 1st flatus
Time to 1st dietwithin 4 weeksInterval between SICU admission and 1st diet

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026